Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:selective_estrogen_receptor_modulator |
| gptkbp:approvalYear |
1977
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
gptkb:L02BA01
|
| gptkbp:CASNumber |
54965-24-1
|
| gptkbp:chemicalFormula |
C32H37NO8
|
| gptkbp:discoveredBy |
gptkb:ICI_Pharmaceuticals
|
| gptkbp:eliminationHalfLife |
5-7 days
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
estrogen receptor antagonist
|
| gptkbp:metabolism |
gptkb:CYP2D6
gptkb:CYP3A4 |
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:proteinBinding |
99%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
fatigue increased risk of blood clots hot flashes |
| gptkbp:synonym |
gptkb:Nolvadex
gptkb:Soltamox |
| gptkbp:usedFor |
breast cancer treatment
breast cancer prevention |
| gptkbp:bfsParent |
gptkb:Soltamox
|
| gptkbp:bfsLayer |
7
|
| http://www.w3.org/2000/01/rdf-schema#label |
tamoxifen citrate
|